1541 — ImmuneOnco Biopharmaceuticals (Shanghai) Cashflow Statement
0.000.00%
Last trade - 00:00- HK$1.47bn
- HK$562.47m
- CNY154.29m
Annual cashflow statement for ImmuneOnco Biopharmaceuticals (Shanghai), fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -733 | -403 | -379 | -317 | -219 |
| Depreciation | |||||
| Non-Cash Items | 555 | 134 | 75.4 | 49.1 | 28.6 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -25.7 | 12.5 | -86.1 | 119 | -26.5 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -191 | -239 | -368 | -128 | -203 |
| Capital Expenditures | -125 | -23.2 | -2.69 | -10.4 | -1.31 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 16.5 | 23.3 | -292 | 48.4 | 11 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -109 | 0.049 | -295 | 37.9 | 9.73 |
| Financing Cash Flow Items | -3.17 | -4.39 | -30.5 | -6.99 | -10.2 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 793 | 179 | 331 | 259 | 402 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 485 | -33.1 | -328 | 171 | 202 |